DXB.ASX: Dimerix Expands Pipeline with Acquisition of Phase 2 Asset

Dimerix Expands Pipeline with Acquisition of Phase 2 Asset

Stock	Dimerix Ltd (DXB.ASX)
Release Time	17 Jul 2026, 9:03 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Dimerix Acquires Phase 2 Asset for Acute Kidney Injury

Key Points

Dimerix acquires DMX-652, a Phase 2-ready asset for acute kidney injury
DMX-652 has a strong safety profile and potential to address significant unmet need
Acquisition aligns with Dimerix's strategy to expand its renal disease pipeline

Full Summary

Dimerix Limited, a clinical-stage biopharmaceutical company, has acquired DMX-652, a Phase 2-ready asset for acute kidney injury (AKI) from Mission Therapeutics. DMX-652 is a selective inhibitor of USP30, designed to support mitochondrial quality control in injured kidney cells. The acquisition includes an open US Investigational New Drug (IND) application, a Phase 2 clinical trial protocol approved by the FDA, and sufficient pharmaceutical grade drug product. DMX-652 has demonstrated promising safety and efficacy in a Phase 1 trial, with no serious adverse events reported. The acquisition aligns with Dimerix's strategy to build a focused pipeline of treatments for rare kidney diseases, complementing its ongoing Phase 3 trial for DMX-200 in focal segmental glomerulosclerosis (FSGS).

Outlook

The acquisition of DMX-652 is expected to create substantial shareholder value, diversify Dimerix's clinical pipeline, and deliver multiple near- and medium-term catalysts for ASX investors.